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Summary 
Human immunoglobulin M (IgM) rheumatoid factors (RFs) show primary direct enzyme-linked 
immunosorbent assay  (ELISA) reactivity with Fab rather than Fc fragments of monoclonal antibody 
(mAb) II-481 directed against the Fc3'-binding site of herpes simplex virus glycoprotein gE. This 
preferential anti-Fab specificity suggests that RFs react with antigen-binding portions of mAb 
II-481 as anti-idiotypic  antibodies directed at the combining site regions of mAb reacting with 
the Fc3'-binding region of gE. Analysis of this idiotype-anti-idiotype reaction employed polymerase 
chain reaction amplification and sequencing of the variable heavy and light (VH and VL) regions 
of mAb 11-481. When VH and VL regions of mAb II-481 were synthesized as overlapping 7-met 
peptides on polypropylene pins, a panel of 10 polyclonal and 6 rnonoclonal  human IgM RFs 
reacted primarily with epitopes within the three solvent-exposed mAb 11-481 complementarity 
determining regions (CDRs). Preincubation  of single CDR heptamer peptides with IgM RFs 
in free solution,  resulted in 63-100%  inhibition of RF binding to mAb II-481 on the ELISA 
plate, confirming the antigenic importance of  linear CDR regions for RF reactivity. Combinations 
of two or three CDR peptides frequently produced 94-100%  inhibition of RF binding to whole 
mAb II-481. Control peptides, singly or in combination, showed no inhibition. Computer modeling 
suggested that the R.F-reactive mAb II-481 Fv region and a previously demonstrated R.F-reactive 
CH3 epitope displayed considerable three-dimensional similarities in conformation. These studies 
may provide insight into limited shape homologies possibly  involved  in an R.F anti-idiotypic reaction. 
H 
uman RFs represent one of the first types of autoanti- 
bodies ever described (1, 2), and over the five decades 
since their initial description, have provided a fascinating sub- 
ject to study in parallel with the humoral immune response 
in rheumatoid arthritis  (RA): (3-7). The original observa- 
tions on immunochemical  and serologic reactions of RFs in- 
dicated that they represented autoantibodies directed at sites 
on the Fc region of human IgG. Indeed the primary anti-Fc 
specificity of human RFs was supported by formation of 22S 
and 11S complexes when 19S IgM or 7S IgG RFs reacted 
with autologous IgG (3-5). Moreover, anti-Fc specificity of 
human RFs was also supported by a multitude of studies of 
antiallotypic RF specificity for Gm determinants dependent 
1 Abbreviations used in thispaper: FR1, framework  region 1; gE, glycopro- 
tein E; R.A, rheumatoid  arthritis. 
on localized single or double amino acid substitutions within 
various regions of CH3 and CH2 of the Fc portion of IgG 
(8-10). 
Recently, there have been a number of indications  that, 
besides Fc, human RFs may have other parallel specificities 
such as the Pab portion of monoclonal mouse IgG antibodies 
directed at the Fc'y-binding region of the HSV glycoprotein 
E (gE) (11, 12). The reaction of human IgM RFs from pa- 
tients with RA with the mouse monoclonal IgG-2b  anti- 
body II-481 to gE (the HSV-1 Fcy-binding protein) was shown 
to resemble an idiotype-anti-idiotype reaction since, in most 
instances, RFs reacted much more strongly with Fab than 
with Fc fragments of mAb II-481 (12). If R.Fs from patients 
with RA react as anti-idiotypes  against  the Fv regions  of 
mAb I1-481 directed at the Fcy-binding regions of gE, then 
the Fab portion and presumably  the three CDRs of mAb 
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very similar or identical to RF-reactive regions on the Fc por- 
tion of IgG (13,  14).  The present report provides evidence 
which supports that this is indeed the case. Moreover, data 
presented here also provide molecular and single amino acid 
epitope definition of an idiotype-anti-idiotype reaction be- 
tween a common human autoantibody (R,F) and the Fv por- 
tion of mAb  II-481  directed at  the Fc3/-binding region of 
the herpes simplex gE (14). The results presented here also 
suggest that  similar conformations may be shared between 
the RF-reactive Fv regions of mAb  II-481 and RF-reactive 
sites  on CH3  of IgG. 
Materials and Methods 
Mouse Monoclonal Cell Lin~  The cell line II-481 B-2.4 producing 
the IgG-2b mouse mAb 11-481 (15) directed at gE of HSV-1 was 
kindly provided by Dr. Pat Spear (Northwestern University Med- 
ical School, Chicago, IL) and was grown in OPTI-MEM media 
(GIBCO BRL, Gaithersburg, MD) supplemented with 5% FCS, 
0.3 mg glutamine, 100 U  of penicillin, and 0.1 mg streptomycin 
(Sigma Chemical Co., St. Louis, MO) per ml. Cells were collected 
by centrifugation and supernatants tested for reactivity with iso- 
lated gE (5 ~g/ml) as well as with whole HSV-1 by ELISA (11, 
12). The cell  line mAb  product 11-481 showed  strong  anti-gE 
specificity. 
mRNA Isolation and cDNA Synthesis.  mRNA was isolated from 
3  x  10  s cells  using  the  Fast  Track  mRNA  Isolation Kit  (In- 
vitrogen, San Diego, CA). Briefly, cells were lysed in detergent- 
based buffer containing RNase and protein degrader and applied 
to oligo (dT) cellulose for adsorption. DNA, dissolved membranes, 
proteins, cell debris,  and nonpolyadenylated RNAs were washed 
off the resin with salt buffers while the mRNA was eluted in the 
absence of salt. Purity and concentration of the mRNA was deter- 
mined spectrophotometrically. Transcription of mRNA into first 
strand cDNA was performed according to the method of Gubler 
and Hoffman (16) with the cDNA Synthesis Kit from Boehringer 
Mannheim Biochemical (Chicago, IL). Briefly, the mRNA sample 
was heated to 65~  for 5 min and then incubated with AMV re- 
verse transcriptase, oligo (dT) 15 primer or random primer, p(dN)6, 
RNase inhibitor, and deoxynucleotide mixture at 42~  for 1 h. 
Oligonucleotide Primers.  The oligonucleotide primers used in 
PCR are shown in Fig. 1. The 5' primer for the light and 3' primers 
for the L and H chains were those of Larrick and co-workers (17, 
18) whereas the 5' primer for the H  chain was from Orlandi et 
al.  (19). Originally, the primers were designed from known se- 
quences of mouse IgG antibodies (20, 21). The 5' primers were 
constructed from information available on conserved sequences of 
the first framework regions (FR1) of L and H chains, whereas the 
3' primers were designed for annealing within the constant regions 
of C K L chains or CH 1 H chains. EcoRI and HindlII restriction 
sites were added to the 5' and 3' primers, respectively. Two bases 
(G) were added outside the restriction endonuclease site to improve 
enzyme digestion. 
PCR.  2/~1 of the cDNA-RNA hybrid and 100 pmol of the 
primer were added to the PCR mixture (GeneAmp; Perkin Elmer 
Cetus, Norwalk, CT) in a total volume of 100/~1. Amplification 
was done in a thermal cycler for 40 cycles (Perkin Elmer Cetus). 
Each cycle consisted of heating to 94~  for 1 min, primer annealing 
at 55~  for 3 rain, and primer extension at 72~  for 3 min. PCR 
products were analyzed with ethidium bromide on a 2% agarose gel. 
Cloning and DNA Sequencing.  PCR bands were reamplified be- 
fore being digested with EcoRI and HindlII restriction enzymes, 
isolated on gel, and ligated into plasmid pGem-3Zf(+) (Promega, 
Madison,  WI). After selection of appropriate clones, each strand 
of the PCR product was sequenced by the dideoxynucleotide chain 
termination method (Sequenase version 2.0 kit; United States Bio- 
chemical  Corp.,  Cleveland,  OH)  using  T7  and  Sp6  primers 
(Promega). mRNA from two separate cell clones was isolated, trans- 
formed to cDNA-RNA hybrids,  and amplified by PCR to assure 
reproducibility of results. Two clones from each amplified VH and 
VL PCR product were selected  and sequenced. 
Study of Human RF Reactivity with VH and VL Primary Amino 
Acid Sequences of mAb 11-481.  The amino acid residues making 
up positions 20-105 on the VH and 14-100  on the VL regions 
of mAb II-481 were synthesized as overlapping 7 mers on Geysen 
pins as previously described (14, 22-27). Pins containing the VH 
or VL primary amino acid sequences were then tested directly with 
a panel of 10 a~nity-isolated polyclonal and 6 monoclonal human 
IgM RFs obtained as previously described (22-24). The procedure 
for testing of the pins containing the overlapping 7 mers of VH 
or VL followed the procedure previously outlined in detail (14). 
Synthesis control pins containing the peptides with the sequences 
PLAC and GLAC were incubated with the positive control mAb 
(PT-02-20027; Cambridge Research Chemicals, Cambridge, MA). 
The next day, the pins were washed four times for 10 rain with 
PBS  containing 0.05%  Tween-20.  Depending  on  the  primary 
reacting antibody, the pins were then incubated with peroxidase- 
conjugated goat F(ab')2 anti-human IgM (for human IgM RF) or 
anti-mouse IgG (Jackson  Laboratories,  West Grove,  PA) diluted 
in PBS containing 1% BSA, 200 #g/well, for 1.5 h at room tem- 
perature. After four wash steps, the pins were incubated with the 
O-phenylene-diamine substrate and color developed for 15 min. After 
completions of assays, a disruption procedure was employed to re- 
move bound antibodies  as previously described  (14, 23, 24). Pins 
could then be reused 25-35 times before losing their antigenicity. 
Synthesis of CDR Peptides and Inhibition of RF Binding to mAb 
11-481.  After  distinct  RF-reactive  linear  sequences  had  been 
identified within the VL or VH CDRs using the pin ELISA assay, 
these reactive regions were synthesized as eight free heptamer pep- 
tides using the original Merrifield technique (28). These CDR pep- 
tides were used in competition/inhibition ELISA assays with RFs 
reacting with mAb 11-481 on the ELISA plate.  Titrations of in- 
creasing amounts of RF reacting with mAb II-481 (5 #g/ml) on 
the plate were used to establish the maximum binding concentra- 
tion of each RF. Concentrations of RF producing 50% maximum 
binding were preincubated with a broad micromolar range of each 
of the eight CDR peptides before completion of the ELISA reac- 
tion between the RF and mAb II-481 on the plate.  In many in- 
stances, various combinations of VL or VH mAb II-481 CDR pep- 
tides were studied to determine if inhibition of RF binding was 
increased using several  peptides derived from different CDR regions. 
Several control peptides were used in parallel.  A laminin peptide 
of the same length but no homologous sequence (CIKVSVS) was 
used  as  one  control.  Additional  control  peptides  included: 
GMERVRWCATDGEG (melanoma peptide); LHNHYT (pep- 
tide from Cv3 of human IgG); CNSRQTDREDELI  (Klebsiella 
peptide); ADAQTDREDLRTLLRY (HLA B27 peptide); AAE- 
DWCKKGDT (IgA Cy3 peptide); and NSRQTDR (KlebsieUa  pep- 
tide).  Positive control inhibition was obtained with whole mAb 
11-481 or Fc of IgG. 
Computer Analysis ofli-481 Sequences.  We used the previously 
established three-dimensional  structure of the Fab portion of mouse 
IgG mAb D1.3 (29) available through the Brookhaven Data Base 
to provide a template for a tentative model of the VH and VL pot- 
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the VH and VL chains of mAb 11-481 were missing because of 
primer annealing, these residues were replaced by the first eight 
amino acids from the VH chain of mAb Id B5.7 (30), and the 
missing residues for the VL chain by those from mAb A17 (31). 
In the comparable FRs of these latter mAbs, the amino acid res- 
idue homologies were 89% identical for the VH and 94% iden- 
tical for VL to those of mAb 11-481. Therefore, it was assumed 
that a similar homology existed for the first eight amino acids in 
the rather conserved  FILl regions of  mAbs Id B5.7, A17, and II-481. 
The sequences of the Fab portions  of mouse mAb D1.3 and 
human mAb 11-481 were aligned using the BESTFIT sub-routine 
of the GCG package (version 7.0;  Genetics Computer Group, 
Madison, WI) (32). The overall identity was 80% for the L chain 
and 81% for the H chain and thus justified  the use of standard 
methods of modeling by homology. The program used was Sybyl 
version 6.0 (Tripos Associates, Inc., St. Louis, MO) running on 
the VAX 4000-60 workstation.  Structures were displayed on the 
Evans and Sutherland PS390 graphics system. 
The loops of the H chain were modeled using the LOOP subrou- 
tine from Sybyl and the backbones displaying the smallest random 
mean square deviation values were selected. Individual amino acid 
substitutions  were made using  the MUTATE command  in the 
BIOPOLYMER module. After the whole H chain was built, the 
structure  was  optimized  for  side-chain geometry  and  energy 
minimized employing the MAXIMIN2 module (1,000 cycles, no 
electrostatics, and vacuum conditions) with a standard Tripos force 
field. 
To model the L chain of the Fab portion of IgG mAb II-481, 
the H chain ofmAb D1.3 was replaced  with the above constructed 
H chain of mAb II-481 and the resulting hybrid was used in the 
subsequent modeling. An attempt to model both chains separately 
did not provide satisfactory  results. Therefore, the loops containing 
residues 26-32 and 90-96 of the L chain were modeled in the hy- 
brid as described for the H chain. The whole structure  was op- 
timized for the side chain geometry and energy minimized as de- 
scribed above for the H chain modeling. In particular, the linear 
amino  acid sequences within the three solvent-accessible CDR 
regions of the VL and VH of mAb II-481, which showed direct 
reactivity with tLFs in pin ELISA, could be visualized and their 
physical proximity estimated. This strategy also allowed for con- 
struction  of a tentative shape of the mAb II-481 combining  site 
using space-fiUing  spheres based on Connolly solvent-accessible  sur- 
faces (33). The whole modeling procedure was verified by using 
VL and VH sequences  of other IgG 2bK mouse mAbs such as IL19.9 
(34, 35) which had already been extensively studied with respect 
to  three-dimensional  crystal  structures.  The validation process 
confirmed that the modeling  steps we used accurately predicted 
most elements of Fv structure  of previously studied mouse IgG 
2bK antibodies where the crystal structures had been established. 
However, these predictions, of  course, were not always perfect since 
the hypervariable  regions of some antibodies actually assumed only 
one of several possible conformations. 
Results 
mRNA from the hybridoma cell line producing mAb II- 
481 was isolated and transformed by reverse transcriptase to 
cDNA-RNA hybrids. When the DNA sequence of the VL 
and VH regions of the Fv portion of mAb II-481 was amplified 
by PCR from the cDNA-RNA hybrids, the L chain primer 
pair (5'-EcoRI/FR1-ML [K] and 3'-HindlII/ML [K] constant) 
gave a major PCtL product of *400 bp whereas the H chain 
Mouse light kappa chain 
Amino acids  1-8 
5':  Eco  RI/FR1-ML(kappa): 
5'-GGGAATTCGA(CT)ATTGTG(AC)T(AG)AC(AC)CA(AG)(GT)(AC)TCAA-3' 
EcoRI 
Amino acids  116-122 
3':  Hind  III/ML(kappa)  const: 
5'-GGAAGCTTACTGGATGGTGGGAAGATGGA-3' 
HindIII 
Mouse heavy gamma chain 
Amino acid  1-8 
5':  Eco  RI/VHIBack(FR1): 
5'-GGGAATTCAGGT(CG)(AC)A(AG)CTGCAG(CG)AGTC(AT)GG-3' 
EcoRI 
Amino  acid  121-131 
3':  Hind  III/MH(gamma)const: 
5' - GGAAGCI-TA  (TC) CTCCACACACAGG  (AG) (AG)  CCAGTGGATAGAC  - 3' 
HindIII 
Figure  1.  5' and 3' end oligonucleotide  PCtL primers for mouse vari- 
able light K  chain and mouse  variable  heavy  3' chain. Bases in parentheses 
stands for equimolar  amounts  of  bases at that position. The 5' end restric- 
tion enzyme  site  EcoRI  and the 3' end restriction  site  HindlII  are underlined. 
primer pair (5'-EcoRI/VH1 Back [FR1] and 3'-HindlII/MH 
[3'] constant)  gave a band of m410 bp (Fig.  2). 
After the PCR products were ligated into plasmid pGem 
3Zf(+), they were cloned and sequenced. The nucleotide and 
amino acid sequences of the L and H  chain variable regions 
including the four FR and three CDR regions are shown 
in Fig. 3, A  and B. The variable L and H chain regions con- 
sisted of 107 and 113 amino acid residues, respectively. The 
L chain was identified as mouse K subgroup I and the H chain 
as subgroup IB (21). 
mRNA  of two  independent  clones  from  the mAb  II- 
481-producing cell line was isolated and from each PCR- 
amplified mRNA-cDNA hybrid, two clones were selected 
and completely sequenced. In all, four separate sequences from 
the VL and four from the VH were obtained. No mutations 
were detected in the four sequenced clones from L chain. In 
one of the four clones from the H  chain, G was substituted 
for C at amino acid 77, changing the corresponding amino 
acid residue Gln to His at  this position. 
Figure 2.  PCR products of the vari- 
able part of mouse mAb II-481 L (lane 
2) and H (lane 3) chains. 10/zl from a 
100-/zl  PCR reaction  was applied  in each 
lane on a 2% agarose  gel stained with 
ethidium bromide together  with a 1-kb 
marker ladder (lane 1). 
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9  i0 
5"-TTC GAT ATT GTG ATA ACA CAG GCT CAA TCA TCT CTG GCT GTG TCT 
Primer  Ser  Ser  Leu Ala  Val  Set 
FRI  20  ..........  27A 27B-27C 
GCA GGA GAA AAG GTC ACT ATG ACC TGT AAG TCC AGT CAA AGT GTT TTA 
Ala Gly  Glu  Lys  Val  Thr  Met Thr  Cys  Lys  Ser  Ser  Gin  Ser  Val  Leu 
27D 27E-27F CDRI----30  ..............  dO 
TAC AGT TCA GAT CAT AAG AAC TAT TTG GCC TGG TAC CAG CAG AAA CCA 
Tyr Ser  Ser  Asp His  Lys  ASh Tyr Leu Ala Trp  Tyr Gin  Gin  Lys  Pro 
FR2  50  ........  CDR2  ....... 
GGA CAG TCF CCT AAA CTA CTG ATC TAC TGG GCA TCC ACT AGB GAA TCT 
Gly  G~n  Ser  Pro Lys  Leu  Leu  lie  Tyr Trp Ala  Ser  Thr Arg G]u  Ser 
60  70 
GGT GTC CCT GAT CGC  TTC ACA GGC AGT GGA TCT GGG  ACA GAT TTT ACT 
Gly  Val  Pro Asp Arg  Phe Thr Gly  Ser Gly  Ser Gly  Thr Asp  Phe Thr 
FR3  80 
CTT ACC ATC AAC AAT GTA CAA ACT GAA GAC CTG GCA GTT TAT 
Leu Thr lle Ash ASh Va] Gin T~r Glu Asp Leu Ala Va] Tyr 
B 
9  IO 
5'  AG GTG CAG CTG CAG GAG TCA GGC  CCT GGG ATT TTG CAG CCC  TCC 
Primer  Pro  G~y  lle  Leu  Gin  Pro  Ser 
20  FRI  30  -- 
CAG ACC CTC AGT CTG ACT TGT TCT TTC TCT GGG  TTT TCA CTG ACC ACT 
Gin  Thr  Leu  Ser  Leu  Thr  Cys  Ser  Phe Ser Gly  Phe  Ser  Leu  Thr  Thr 
-  -CDRI  ......  35A-3SB  40  FR2 
TAT GGT ATA GGA GTG GGC  TGG ATT CGT CAG CCT TCA GGG AAG GGT CTG 
Tyr Gly  lle  Gly  Va]  Gly  Trp  lle  Arg  Gin  Pro  Ser  Gly  Lys  Gly  Leu 
50  ....................  CDR2  ........  60  .... 
GAG TGG CTG GCA CAC ATT TGG TGG AAT GAT AAT AAG TTC TAT AAC ACA 
Glu  Trp  Leu Ala  His  Ile  Trp  Trp Ash Asp ASh  LyS  Phe  Tyr  Ash  Thr 
..........  70  FR3 
GTC CTG AAG AGC CGG CTC ACA ATC TCC AGG  GAC ACC TCC AAC AAC CAG 
Val  Leu  Lys  Ser Arg  Leu Thr  lle  Ser Arg Asp Thr  Ser Ash Ash  Gin 
80  82A 82B 82C  90 
TTC TGT  GTA TTC CTC AGG  ATC GCC AGT ATG GAC ACT GCA GAT ACT GCC ACA TAG 
Phe  Cys  Va]  Phe  Leu Arg  lle  A]a Ser  Met Asp Thr Ala  Asp Thr Ala  Thr Tyr 
---90-  -CDR3----94  96  ....  100  FR4 
CAT  CAA TAC CTC TCC TCG  TTC  ACG  TTC  GGA GGG GGG ACC AAG CTG GAA 
His Gin  Tyr Leu Ser Ser  Phe lhr  Phe Gly  G]y  Gly  Thr  Lys  Leu Glu 
107  II0  CL 
ATA CAA CGG GCT GAT GCT GCA CCA ACT GTA TCC ATC TTC CCA 
Ile  Gin  Arg Ala  Asp Ala Ala  Pro  Thr  Val  Primer 
CCA TCC 
AGT AAG CTT 
..........  CDR3- --IO0-100A  ....... 
TAC TGT GCT CGG ATG AGG GAC GGG GCC TGG TT, GCT TAC TGG GGC CAA 
Tyr  Cys  A]a Arg  Met Arg Asp Gly  A1a Trp  Phe Ala  Tyr Trp Gly  Gin 
FR4  ]I0  113  CHI  120 
GGG ACT CTG GTC ACT GTC TCT GCA GCC AAA ACA ACA CCC CCA TCA GTC 
Gly T~r  Leu Val  Thr Val  Ser  Ala  Ala  Lys  ~hr  Thr  Pro  Pro  Set 
TAT CCA CTG GTT CCT GTG TGT GGA GATAA 
Primer 
Figure  3.  (A)  Sequence  of the 
variable part of mouse mAb II-481 
L chain  (amino acids 9-107)  with 
FR  and  CDR.  Primers and  part 
of constant  light  (CL)  chain  se- 
quences  (amino acids 108-115  are 
also  shown).  (B) Sequence  of the 
variable part of mouse mAb II-481 
H chain (amino acids 1-113) with 
FR and CDR. Primers and part of 
constant  H  chain region  1 (CH1; 
amino acids 114-120) sequences are 
also shown. These sequence data are 
available  from  EMBL/GenBank/ 
DDBJ  under  accession  numbers 
X81462 (H chain) and X81463  (L 
chain). 
Human Potyclonal and Monoclonal RFs React with 7 mers of 
mAb 11-481 VII and VL Primary Amino Acid Sequence  When 
the entire VH sequence of mAb II-481  was synthesized as 
overlapping 7 mers on Geysen pins and tested for reactivity 
with polyclonal RFs, four to five major regions of positive 
reactivity were identified.  Localized major positively reacting 
regions were found at 7 mers beginning with residues 20-27, 
32-39,  44-58,  and 94-105  on the VH segment.  Some RFs 
also showed moderate reactions with 7 mers at positions 65-68. 
All of the major reactive VH-region sites were solvent acces- 
sible.  Some variability  was noted from RF to RF in terms 
of exact  localization and  numbers  of reactive  VH regions. 
However, the overall patterns  of reactive ELISA profiles for 
most polyclonal RFs were remarkably  similar. An example 
of results obtained with individual  RFs is shown in Fig. 4 A. 
When the VL sequence ofmAb II-481 was also tested with 
the same panel of polyclonal RFs, localized reactive epitopes 
were found at 7 mers beginning with residues 25-32, 31-38, 
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Figure  4.  (A) Example of results 
of pin ELISA assays done with pins 
encompassing residues 20-105 of the 
variable H  chain of mouse mono- 
clonal  II-481  as  overlapping  hep- 
tamers  on  each pin.  The  residue 
numbers  are  shown  on  the 
horizontal axis. Residues within the 
CDR-1,  -2,  and  -3  regions  are 
shown in capital letters. Optical den- 
sities of ELISA assays done with 1 
of 10 polyclonal IgM RF (Cla) and 
the heptamer peptide on each pin 
are shown as vertical bars. (B and 
C) Examples of result of pin ELISA 
assay done with pins encompassing 
residues  14-100  of the variable L 
chain of mouse monoclonal II-481 
as overlapping  heptamers on each 
pin. The residue numbers are shown 
on horizontal axis and the residues 
within the three CDR regions are 
designated in capital letters. Optical 
densities of ELISA assays done with 
2 of the 10 polyclonal IgM RFs and 
the heptamer peptide  on each pin 
are shown as vertical bars. 
1876  Monoclonal Anti-Fcy Ab Contains  CDR Regions Reacting with RFs 46-53, 56-64, 69-72, and 85-97. All of these reactive regions 
were judged to be solvent accessible. Again, some variability 
was noted from RF to RF in terms of exact localization  and 
number of the most reactive VL regions.  Examples  of the 
profiles of RF VL reactivity  are shown in Fig. 4, B and C. 
No correlation could be found between patterns of RF CDR 
or  VH/VL  reactivity  and  RF  anti-IgG  subclass  or  Gm 
specificity. 
Monoclonal human IgM RFs generated from B cells of 
patients  with RA were  also tested with the overlapping  7 
mers of the VH and VL II-481 sequence. Major VH and VL 
regions of RF reactivity were similar to those previously ob- 
served with the polyclonal IgM RFs. Individual monoclonal 
RFs reacted with all or some of these sites. Examples of mono- 
clonal  RF patterns of VH and VL reactivity  are shown in 
Fig.  5, A  and B.  Overall,  the monoclonal RFs duplicated 
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1877  Johansson  et al. similar patterns recorded with many of the polyclonal RFs 
previously studied, although exact localization and numbers 
of reactive regions  varied slightly. 
ELISAs performed  with control antibodies including normal 
polyclonal human IgM without RF activity as well as mono- 
donal Waldenstr6m's IgM paraproteins, also without RF ac- 
tivity,  were completely  negative with the entire set of syn- 
thetic peptides corresponding  to the VH and VL of mAb 
II-481 (data not shown). 
Human Polyclonal and Monoclonal IgM RFs React Primarily 
with CDR Regions  on VH and VL Chains  of  mAb 11-481.  After 
the reactivity profile of each polyclonal and monoclonal human 
IgM RF against the VH and VL overlapping 7 mers ofmAb 
II-481 was established by pin ELISA, it became clear that 
both polyclonal and monoclonal RFs reacted predominantly 
with regions on both VH and VL chains which were ex- 
tremely close to or within CDR-1, -2, and -3 regions of mAb 
II-481. All of the reactive CDR regions were solvent acces- 
sible and therefore could be considered as important poten- 
tial antigenic  sites. 
The profiles of reactivity of polyclonal IgM RF with re- 
spect to the VH CDR regions are shown in Table 1. It can 
be seen that 6 of the 10 polyclonal IgM RFs tested reacted 
with heptamers that included one or more amino acid residues 
from all three CDR regions. Four RFs reacted with two of 
the three CDRs. The profiles of the same 10 polyclonal RFs' 
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Figure  5.  (A) Example of results 
of pin ELISA assays  done with pins 
encompassing  residues  20-105 of the 
variable H chain of mouse mono- 
clonal  II-481  as  overlapping  hep- 
tamers  on  each  pin.  The  residue 
numbers beginning each 7 met are 
shown on the horizontal  axis. Op- 
tical densities of ELISA assays done 
with monoclonal IgM RF N28 and 
the heptamer peptide on each pin 
are shown as vertical bars. (B) Ex- 
ample of result of pin ELISA assay 
done  with  pins  encompassing 
residues  14-100 of the variable L 
chain of mouse monoclonal 11-481 
as overlapping  heptamers on each 
pin.  Optical  densities  of  ELISA 
assays done  with  one  of the  six 
monoclonal IgM RFs and the hep- 
tamer peptide on each pin are shown 
as vertical bars. 
1878  Monoclonal Anti-Fc'y  Ab Contains  CDR Regions  Reacting  with RFs reactivity with mAb 11-481 VL 7 mers are shown in Table 
2. Five ILFs reacted with epitopes from all three CDR regions, 
two reacted with two CDRs, and three with only one CDR. 
Of interest was the epitope represented by SGVPDRF which 
occurred largely just after the second CDP, in the FR3 re- 
gion. This region contained only one residue (the serine at 
position 56) within the CDR-2. 
For monoclonal IgM RFs, the profile of VH reactivity is 
shown in Table 3. Four of the six monoclonal RFs reacted 
with 7 mers which included one or more residues  from all 
three CDRs. One monoclonal RF reacted with two CDRs 
and one (H4) with only one CDR. The VL reactivity profile 
for three monodonal IgM RF is shown in Table 4. Two of 
three showed reactions with residues within all three CDRe; 
the third (H4) showed a strong reaction with only one CDP,. 
Cross-inhibition of lgM RF Reacting with mAb 11-481 Using 
mAb 11-481 CDR Peptides,  A series of inhibition experiments 
was conducted in which polyclonal IgM RFs known to react 
with the Fab portion of mAb II-481 were preincubated with 
peptides synthesized from the CDR RF-reactive regions of 
mAb II-481 before completion of the ELISA reaction between 
RFs and mAb II-481  on the ELISA plate. 
Results of competition ELISA assays using peptides from 
the three CDRs of mAb II-481 to inhibit the binding of var- 
ious polyclonal IgM RFs to I1-481 on the ELISA plate are 
shown in Table 5 and Fig. 6. It can be seen that the patterns 
of CDR peptide inhibition were quite different for each RF 
tested and that within the profile of peptides tested, at least 
one CDR 7-mer peptide showed maximum inhibition for 
each RF (63-100%). Results of these inhibition experiments 
correlated quite well with the pin ELISA direct binding assays 
where the entire I1-481 VH or VL linear sequence had been 
previously assayed. Of interest was the major degree of inhi- 
bition (62-90%) recorded with the SGVPDRF peptide from 
the  CDP,-1  VL region  and the high levels of inhibition 
(80-100%) found with CDR-2 VH peptide HIWWNDN 
when individual polyclonal IgM RFs were tested. Fig. 6 shows 
final 96% inhibition for CDR-2 VH peptide HIWWNDN 
with P,F AGEB. and a broad range of lesser inhibition with 
the other CDR peptides tested. No inhibition was recorded 
Table  1.  Polyclonal  IgM RF profiles with Variable Heavy Chain of Mouse mAb 11-481 
Polyclonal 
IgM RF  CDR1 Region  CDR2 Region  CDR3 Region 
Age  YG I GVGW*  EWLAH I W  DGAWFAY 
RDGAWFA 
MRDGAWF 
Abr  YGIGVGW  LEWLAHI  RDGAWFA 
AHIWWND  DGAWFAY 
Cla  YGIGVGW  EWLAHIW  DGAWFAY 
HI WWNDN  RDGAWFA 
(LTISRDT)  MRDGAWF 
Har  None  GLEWLAH  RDGAWFA 
HI WWNDN  MRDGAWF 
Lop  YGIGVGW  GLEWLAH  DGAWFAY 
LEWLAHI  RDGAWFA 
HI WWNDN 
New  TYGIGVG  FYNTVLK 
McC  TTYGIGV  GLEWLAH 
EWLAHIW 
HI WWNDN 
Sot  GIGVGWI  EWLAHIW 
WLAHIWW 
LAHIWWN 
Str  None  GLEWLAH 
HI WWNDN 
Wea  None  HIWWNDN 
None 
MRDGAWF 
RDGAWFA 
FAYWGQG 
AWFAYWG 
GAWFAYW 
DGAWFAY 
MRDGAWF 
RDGAWFA 
* Reactive residues within or adjacent to each CDR are shown as single letter amino acid designation; residues underlined  are actually  within the 
respective CDRs. When several reactive 7 mers are shown beneath a single CDR, the first sequence listed showed maximum  reactivity  with test 
RF. Residues shown in parentheses were weakly positive in ELISA reactions with RFs. 
1879  Johansson  et al. Table  2.  Po~cbnal ~M RF Profi~ with Variable L  Chain ~  Mouse mAb H-481 
Polyclonal 
IgM RF  CDR1 Region  CDR2 Region  CDR3 Region 
Age  SSQSVLY*  LLIYWAS  YFCHQYL 
SQSVLYS  LIYWAST  FCHQYLS 
NYLAWYQ  SGVPDRF  CHQYLSS 
YLAWYQQ  GVPDRFT  HQYLSSF 
Abr  VLYSSDH  YWASTRE  (HQYLSFT) 
SGVPDRF 
GVPDRFT 
Cla  VLYSSDH  LIYWAST  YFCHQYL 
NYLAWYQ  SGVPDRF 
GVPDRFT 
Har  None  SGVPDRF  None 
Lop  SQSVLYS  YWASTRE  YFCHQYL 
SSQSVLY  SGVPDRF 
VLYSSDH  GVPDRFT 
NYLAWY 
McC  NYLAWYQ  SGVPDRF  AVYFC~ 
YLAWYQQ  GVPDRFT 
New  KVTMTCK  LIYWASTR  None 
VTMTCKS 
TMTCKSS 
Sor  VLYSSDH  YWASTR  None 
NYLAWYQ  S_GVPDRF 
GVPDRFT 
Sti  None  SGVPDRF  None 
GVPDRFT 
Wea  None  SGVPDRF  None 
GVPDRFT 
* Residues underlined  are actually  within respective CDR. The first 7 mers listed  showed  maximum  RF reactivity  and those shown  below, positive 
RF ELISA reactions but of lesser magnitude. 
for the control laminin 7-met peptide CIKVAVS or the five 
other control peptides, and complete inhibition was always 
recorded when either whole Fc fragment or mAb 11-481 was 
used as inhibitor. When mAb II-481  CDR peptides were 
used as inhibitors of RFs binding to whole II-481  on the 
ELISA plate, a broad range of micromolar concentrations of 
peptides were tested and maximum inhibition of RF binding 
was found with highest peptide concentrations tested. By 
contrast, much lower concentrations of whole Fc or whole 
mAb II-481 were sufficient for complete inhibition (Fig. 6). 
It can be seen from Table 5 that with all RFs tested for 
inhibition using single CDR peptides, usually one or two 
such peptides showed highest levels of inhibition varying from 
28-100%. In no instance did any of the panel of six control 
peptides show inhibition. Accordingly, a second kind of in- 
hibition experiment was conducted in which combinations 
of two or three I1-481 CDR peptides were tested for inhibi- 
tion of RF binding to mAb II-481 on the ELISA plate. Typ- 
ical results are shown in Table 6. It can be seen that combina- 
tions of two or three CDR peptides almost always showed 
an increment of inhibition beyond what had been recorded 
with the single CDR peptides alone. In some instances,  the 
percent inhibition was actually higher than the sum of inhi- 
bitions with the single peptides tested alone as inhibitors, 
and in only two instances (RF LOP and ABR), the two in- 
hibiting peptides studied together did not far surpass the de- 
gree of inhibition recorded when the CDR. peptides were 
tested alone. From Table 6 it can also be seen that combina- 
tions of two or three CDR peptides produced 50-100% in- 
hibition with 88-100% inhibition in 10 of 12 experiments. 
The fact that two or sometimes three CDR peptides pro- 
duced an increment in observed  inhibition of RF binding 
over  what had been recorded with  single CDR peptides 
provided additional confirmation of the validity of the assays. 
1880  Monoclonal  Anti-Fcy  Ab Contains CDR Regions Reacting with RFs Table  3.  Monoclonal  IgM RF Profiles with Variable H  Chain of Mouse mAb 11-481 
Monoclonal 
IgM RF  CDR1  Region  CDR2  Region  CDR3  Region 
D53  EWLAH I W 
N28 
WWNDNKF 
WNDNKFY 
EWLAH  W 
WLAH  WW 
LAH  WWN 
H6 
YGIGVGW* 
GIGVGWI 
IGVGWIR 
SFSGFSL 
FSGFSLT 
GFSLTTY 
GIGVGWl 
GVGWIRQ 
VGWIRQP 
GFSLTTY 
SLTTYGI 
YGIGVGW 
GIGVGWl 
EWLAH  W 
WLAH  WW 
LAH  WWN 
H4  None  EWLAH  W 
WWNDNKF 
WNDNKFY 
FYNTVLK 
DGAWFAY 
GAWFAYW 
AWFAYWG 
GAWFAYW 
AYWGQGT 
MRDGAWF 
RDGAWFA 
DGAWFAY 
GAWFAYW 
AWFAYWG 
WFAYWGQ 
None 
RF  114  VGW I RQP  EWLAH I W  None 
WLAH I WW 
G4  TYGIGVG  EWLAHIW  YYCARMR 
GVGWlRQ  WLAHIWW 
KFYNTVL 
* Residues  within respective  CDR are shown as underlined.  When several reactive  7 mers  are shown beneath  a single  CDR, the first  sequence 
listed  showed maximum RF reactivity. 
Table  4.  Monoclonal  IgM RF Profiles with Variable L  Chain of Mouse mAb 11-481 
Monoclonal  IgM RF  CDR1  Region  CDR2  Region  CDR3  Region 
D53  LYSSDHK*  PKLLIYW  YFCHQYL 
YSSDHKN  KLLIYWA  LAVYFCH 
SDHKNYL  LLIYWAS  VYFCHQY 
DHKNYLA 
KNYLAWY 
N28  SSOSVLY 
SOSVLYS 
H4 
KNYLAWY 
NYLAWYQ 
LYSSDHK 
YSSDHKN 
LIYWAST 
(LIYWAST)t 
QYLSSFT 
None 
* Residues  within respective  CDR are  shown as underlined. 
t H4 reaction  with  L I YWAST was borderline in optical  density  (OD 0.250). 
1881  Johansson  et al. Table 5.  Inhibition of Polyclonal IgM RF Binding to mAb II-481 Using 7-mer Peptides  from  the  VL and VII CDRs 
of mAb 11-481 
Polyclonal IgM RF tested 
Actual sequence of 
mAb II-481  CDR  CDR. peptide  CLAU  AGER  LOP  STR  WEAK  MCC  SOR  ABR 
CDK-1  VL  NYLAWYQ  40*  45  20  28  30  40  45  12 
CDR-1  VL  SQSVLYS  10  12  18  0  0  0  0  6 
CDR-2 VL  SGVPDRF  15  28  25  18  []  [] 
CDR-2  VL  LIYWAST  20  32  8  8  5  8  14  4 
CDR-3  VL  YFCHQYL  10  44  10  0  0  14  0  0 
CDR-X VH  VClCVGW  24  12  0  0  14  40  12 
CDR-2 VH  HIWWNDN  32  []  []  10  26  16  8  ~] 
CDR-3  VH  RDGAWFA  0  40  45  []  4  32  14  22 
Control peptides: 
Laminin  CIKVAVS  0  0  0  0  0  0  0  0 
Human  Cv3  LHNHYT  0  0  0  0  0  0  0  0 
Klebsiella  CNSRQTDREDELI  0  0  0  0  0  0  0  0 
HLA B27  AKAQTDREDLRTLLR.Y  0  0  0  0  0  0  0  0 
IgA C~3  AAEDWCKKGDT  0  0  0  0  0  0  0  0 
Klebsiella  NSRQTDR  0  0  0  0  0  0  0  0 
Whole Fc human  IgG  100  100  100  100  100  100  100  100 
mAb II-481  100  100  100  100  100  100  100  100 
*  Numbers  refer to percent inhibition  of each R.F binding  to mAb II-481 using preincubation with the CDR peptide tested. 
t Experiments where  a single CDR peptide produced 60%  or more inhibition  are boxed. 
Also, in no instance did any combination of two or three 
control peptides  show any inhibition of RF binding (data 
not shown). 
The finding that the isolated immunoreactive peptides such 
as YGIGVGW from the VH CDR-1, SGVPDKF from the 
100 
90  CDR-1 VL SQSVLYS 
a  80  CDR-1 VH YGIGVGW 
Z  CDR-2 VL SGVPDRF 
70  CDR-1VL NYLAWYG 
CDR-2 VL UYWAST 
m 
~-  60  CDR-3 VH RDGAWFA 
Z  CDR-3 VL YFCHQYL 
so 
n- 
40 
3O 
20 
10  F~ 
R-2 VH HIWWNDN 
10-2  10  "1  1  10  102 
[Final Competitor] ~M 
Figure  6.  Competition/inhibition ELISA experiment in which AGER 
poly~lonal IgM KF used at a concentration producing 50%  maximum 
binding for mAb II-481 on the ELISA plate was preincubated with a broad 
range of concentrations  of mAb I1-481, KF-reactive heptapeptides.  Max- 
imum  inhibition  in  this  case  occurred  with  CDK-2  VH  peptide 
HIWWNDN and the positive control Fc of IgG. No inhibition was ob- 
served with control peptides  such  as the laminin peptide  CIKVAVS. 
VL CDK-2, or RDGAWFA from the VH CDR-3 of mAb 
II-481 produced 100-63% inhibition of binding between IgM 
R.Fs and the whole mAb 11-481 confirmed the importance 
of these CDR epitopes reacting with the test RFs. Inhibi- 
tion results using single or combinations  of the CDR pep- 
tides reacting with RFs in free solution confirmed the im- 
portance of these portions of rnAb II-481 CDKs as principal 
sites for RF binding in this idiotype-anti-idiotypic reaction. 
Computer Modeling and Analysis of mAb 11-481 RF-reactive 
Regions.  A three-dimensional representation of the mAb II- 
481 was constructed using the previously established struc- 
tures of mouse mAb D1.3  (29), B5.7 (30), and mAb A17 
(31) as described in Materials and Methods. It was quite clear 
that major differences in conformation appeared within the 
Fv regions of the respective molecules (Fig. 7, A and B). The 
solvent-accessible, RF-reactive CDR regions of mAb 11-481 
were then highlighted on our model and are shown in Fig. 
7 C with blue highlighting the H chain RF-reactive CDRs 
and yellow, the L chain RF-reactive CDK regions. An esti- 
mate of the actual shape of the mAb I1-481 combining site 
was generated using Connolly solvent-accessible  surfaces  (33). 
This showed that the Fv region of mAb II-481 exhibited a 
characteristic Mexican hat (sombrero) appearance (Fig. 8 A). 
Because this shape very much resembled a prominent RF- 
reactive epitope on CH3 previously studied in some detail 
(36) (Fig. 8 B), direct comparisons of the topographical similar- 
ities of these two RF-reactive regions-the hypothetical too- 
1882  Monoclonal Anti-Fc3, Ab Contains  CDR Regions Reacting with RFs Table  6.  Competition ELISA Results in  Which Polyclonal lgM RF Were Preincubated with Combinations of mAb 11-481 CDR 
Peptides before Completion of the ELISA with mAb 11-481 on the Plate 
Combination of mAb II-481 CDR 
Peptides  Tested in Inhibition 
Polyclonal  IgM RF tested 
CLAU  AGER  LOP  STR  WEAK  MCC  SOR  ABR 
CDR-1  VL NYLAWYQ  (40)* 
94*  Plus CDR-2 VH HIWWNDN  (32)* 
CDR-1  VL NYLAWYQ  (40) 
Plus CDR-2 VL LIYWAST (20)  72 
Plus CDR-2 VH HIWWNDN  (32) 
CDR-1  VL NYLAWYQ (45)  88 
Plus CDR-3 VL YFCHQYL  (44) 
CDP,-1 VL NYLAWYQ (45) 
Plus CDR-3 VL YFCHQYL  (44)  96 
Plus  CDR.-3  VH RDGAWFA  (40) 
CDR.-1  VL NYLAWYQ  (20) 
Plus CDR-2 VL SGVPDRF  (25)  52 
Plus  CDR-3 VH RDGAWFA  (45) 
CDR-1  VL NYLAWYQ  (28)  98 
Plus CDR-3 VH RDGAWFA  (63) 
CDR-1  VL NYLAWYQ (30) 
Plus CDR-2 VL SGVPDRF  (72) 
CDR-1  VL NYLAWYQ  (40) 
Plus CDR-2 VL SGVPDRF  (80) 
CDR-1  VL NYLAWYQ  (45) 
Plus CDR.-2  VL SGVPDRF  (90) 
CDR-1  VL NYLAWYQ  (45) 
Plus CDR-1  VH YGIGVGW (40) 
CDR-2 VL SGVPDRF  (90) 
Plus CDR-1  VH YGIGVGW (40) 
CDR-2 VL SGVPDtLF  (62) 
Plus CDR-2 VH HIWWNDN  (80) 
Lamin control peptide 
CIKVAVS  s  0  0  0  0 
Whole Fc human IgG  100  100  100  100 
100 
100 
100 
100 
100 
50 
0  0  0  0 
100  100  100  100 
* Numbers in parentheses indicate inhibition by single peptide alone (see Table 5). 
* Numbers indicate percent maximum inhibition with indicated combinations of CDR peptides tested over a broad micromolar concentration range. 
s Control peptides tested with RFs included CIKVAVS (laminin); GMERVRWCATDGEG (melanoma); LHNHYT (human Cv3); CNSRQTDREDELI 
(KlebsieUa); ADAQTDREDLRTLLRY (HLA B27); AAEDWCKKGDT (IgA Cs3); and NSRQTDR (Klebsiella). None singly or in combination showed 
any inhibition of RF binding to mAb 11-481. 
deled structure of the Fv portion of mAb II-481 and the pre- 
viously identified CH3 region-were made using the Sybyl 
computer graphics program. The remarkable apparent similar- 
ities in shape between these two different RF-reactive regions 
of entirely different antibody molecules are illustrated in Fig. 
8 C.  When  10 A  sections of the Fv RF-reactive region of 
mAb II-481 were examined (Fig.  8, D  and E), preservation 
of the Mexican hat sombrero configuration was noted at many 
different  levels.  These  comparisons  supported  a  marked 
hypothetical conformational similarity between the two com- 
pletely different RF-reactive Ig domains:  the Fv portion of 
mAb  11-481  and  the  CH3  region  of human  IgG. 
Discussion 
HSV induces  Fcy-binding proteins  on infected cells and 
on virions. These Fc'y-binding proteins are coded for by the 
HSV genome and are able to bind the Fc part of human IgG 
1883  Johansson et al. Figure 7.  (A) Composite  view as produced by Sybyl graphics of the 
template molecule (mouse mAb D1.3) used to produce the model of the 
Fab regions of mAb 11-481 and the actual completed model of II-481. The 
template mAb D1.3 is shown in red and the modeled mAb 11-481  in green 
and yellow. The upper portions containing the VL and VH regions are 
considerably different. (B) An enlarged view of the antibody combining 
sites of both molecules is shown in the two-color mode. The green/yellow 
carbon trace shows the modeled V regions of mAb 11-481 and the red 
represents the same V regions of the template mAb D1.3. (C) Computer 
graphics scheme of Fv region of mAb 11-481 showing RF-reactive residues 
within VL CDRs in yellow and RF-reactive residues within VH CDRs 
in blue. All RF-reactive residues shown in yellow or blue were judged 
to be solvent accessible. 
Figure 8.  (A) Comparative Sybyl computer graphics views of the sur- 
face of the mAb II-481 combining site area (modeled in white showing 
what appears to be a Mexican hat configuration).  The constant regions 
of the molecule shown in blue extend upward to the right. (/3) By com- 
parison, the surface  modeling of a previously established CH3 RF-reactive 
region (EGLHNHY at residues 430-436  in CH3) is shown in red. The 
similarities in overall shape of the two R.F-reactive IgG regions (one at 
the Fv portion of mAb II-481 in white) and the other at an outpouching 
of the IgG CH3 region (in red) are shown when the actual shapes of the 
two RF-reactive regions are overlaid. (D and E) Represents several 10 A 
cuts through the Fv region ofmAb II-481 showing variations of the shape 
at several levels. 
1884  Monoclonal Anti-Fc3, Ab Contains CDR Regions  Reacting with RFs (37-39).  Mouse mAb II-481  reacts with  the HSV-1  Fc'y- 
binding protein, gE, and the binding site of the mAb is directed 
at the Fc binding site on gE (14). 
In the present study we have examined the reactions of 
human polyclonal and monoclonal IgM RFs with mouse mAb 
II-481  directed at the Fc3,-binding glycoprotein of HSV-1 
as an example of an idiotype-anti-idiotype reaction. The op- 
portunity to study this reaction was provided by our previous 
observations  that  many human RFs  reacted with  the Fab 
antigen-binding portions of mAbs to herpesvirus Fcy-binding 
glycoproteins (12,  14). These findings suggested that some 
KFs could be generated as anti-idiotypic antibodies directed 
against HSV-1 Fey-binding proteins (11, 12, 13, 40) as shown 
in Fig.  9.  The reaction between mAb I1-481 and R.F was 
inhibited by either IgG or highly purified gE (the Fcy-binding 
herpes glycoprotein) (11, 12). Moreover, using an entirely 
different mAb (88-S) also directed against the Fc3/-binding 
protein of HSV-2, a similar ILF specificity was demonstrated. 
Positive reactions were recorded for KF reacting with whole 
mAbs II-481  and 88-S and with their Fab but not their Fc 
fragments (12). These findings indicated that combining sites 
of many KFs may react with Fv regions of antibodies reacting 
with Fc3~-binding regions of the two herpesviruses HSV-1 
and HSV-2. 
If RFs from patients with RA react as anti-idiotypes against 
the Fv regions ofmAb II-481, the antibody combining regions, 
therefore, the six (three VH,  three VL) CDKs  of mAb II- 
481  should contain antigenic epitopes very similar or iden- 
tical to antigenic regions on CH3 and CH2 of human IgG 
reacting with human KF. Evidence supporting this latter hy- 
pothesis has been presented in the present report. The pri- 
mary amino acid sequence of the VH and VL regions ofmAb 
11-481 was established by PCK mKNA expansion and se- 
quencing of the eDNA from the cell line producing the mAb. 
When the primary amino acid sequences of VH and VL mAb 
I1-481 had been established, the entire solvent-accessible  VH 
and VL regions of the latter were synthesized and tested as 
overlapping heptamers for RF reactivity. This approach showed 
IgG 
Ab0  --~F(ab),  2 
Fc~BP  i  t  ~  Abl 
Ab2 =RF 
Figure  9,  Anti-idiotTpe hypothesis  regarding a  conceivable assodation 
of vira| Fc~-binding protein and rheumatoid factor (RF). Viral Fc~-binding 
protein on virions and on virus-infected  cells are able to bind the Fc part 
of IgG (AbO). KF might be produced  as anti-idiotypic  antibodies (Ab2) 
against antibodies (AbI) directed  towards  the internal image  of the viral 
Fc'y-binding  proteins. The reactivity  of most R.Fs is also directed  against 
the Fc part of IgG (AbO). 
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regions. Although each polyclonal or monoclonal KF dis- 
played a slightly different reactive profile, the principal anti- 
mAb 11-481 CDK reactivity of all KFs tested was clearly evi- 
dent. No correlation  was noted between anti-IgG subclass 
or anti-Gm specificity of RFs tested and their patterns of re- 
activity with VL or VH linear residues. It is recognized that 
testing RFs with linear  heptamers  of primary sequence is 
clearly not equivalent to assays of the whole Fv region since 
a number of antigenic epitopes on the VL and VH regions 
of mAb  II-481 may be  conformationat and  depend  on 
three-dimensional  structure.  Nevertheless,  the remarkable 
general  overall patterns  of reactivity with  small  solvent- 
accessible linear regions of the CDRs suggest that they may 
contribute to important reactive sites for R.Fs. Further strong 
evidence that the linear regions within the three mAb 11-481 
CDR.s contributed important reactive epitopes for test KFs 
was provided by the CDR peptide inhibition data summa- 
rized in Tables 5 and 6. For each RF, a single CDR peptide 
produced 63-100% inhibition of binding between test RFs 
and whole mAb II-481 on the ELISA plate. With the panels 
of RFs tested, some single CDR peptides or combinations 
of CDK peptides inhibited KF binding to mAb II-481 better 
than others, although many KFs had reacted with most VL 
or VH CDR regions in the pin ELISA assay. It seems pos- 
sible that CDR peptides showing the greatest inhibition ac- 
tually represented portions of the antigenic  sites of II-481 
bearing the greatest avidity for the particular RF being tested. 
These data emphasized that the major peaks of RF reactivity 
within the three CDRs of mAb II-481 synthesized as linear 
overlapping heptamers on the pins were real phenomena and 
could be confirmed by inhibition of KF reactivity using prein- 
cubation of single CDK peptides with IgM KFs in free solu- 
tion. Moreover, increases in KF inhibition to 100%, noted 
when several  combinations of II-481 CDR peptides were em- 
ployed together, further support the significance of their in- 
dividual contributions to RF antigen-binding sites. Since the 
use of single or combinations of CDR peptides could never 
exactly approximate the three-dimensional conformation of 
the mAb II-481 combining site, it often required much higher 
micromolar concentrations of CDK peptide than Fc of IgG 
or mAb II-481 for complete inhibition. This was to be ex- 
pected since the affinity between RF and single or several 
peptides could never exactly reproduce that with the whole 
antibody Fv portion. A complete replication  of the three- 
dimensional configuration of mAb 11-481 CDKs cannot, of 
course, be hoped for with the single linear peptides tested, 
however, the results with peptide  inhibition demonstrated 
that this approach could provide remarkably detailed infor- 
mation concerning RF-reactive  epitopes. 
Finally, the three-dimensional  shape or conformation of 
the Fv portion of mAb 11-481 was modeled using computer 
graphics and coordinates established  for several  template mAbs 
previously studied.  It must be emphasized that our three- 
dimensional model of mAb 11-481 is still theoretical and will 
require confirmation when gE and Fab II-481 have  been crys- 
tallized and studied for their exact three-dimensional  struc- 
ture.  However, when the spacial distribution and shape of 
the Fv portion of mAb II-481 was estimated using approxi- 
mation of the areas of the individual atoms involved, a som- 
brero conformation was found.  This particular  shape bore 
a striking resemblance to a previously identified CH3 epi- 
tope showing strong RF reactivity (36). This latter epitope 
was based on established three-dimensional  CH3 structure 
according to Diesenhoffer et al. (41, 42). Of interest was the 
fact that the CH3 epitope visualized in its three-dimensional 
conformation showed such a striking homology of shape with 
the theoretical model of the Fv region of mAb II-481 con- 
structed using our modeling procedure. This region contained 
the two histidines at positions 433 and 435 and the tyrosine 
at 436, which had previously been identified as important 
epitopes for RF reactivity (43). Although an exact homolo- 
gous sequence to the EGLHNHY at this region (residues 
430-436 in CH3) was not present in the Fv region of mAb 
II-481, it was clear that the two regions shared many similar- 
ities in conformation. Thus a number of separate lines of evi- 
dence presented in the present report provide intimate in- 
sight into precise  residues  within the Fv ofmAb II-481 idiotype 
reacting with RFs in an idiotype-anti-Id reaction. The pri- 
mary reactivity of the polyclonal and monoclonal RF with 
the CDR-1, -2, and -3 regions confirmed that such RFs react 
with regions contributing to the antigen binding sites of mAb 
II-481 directed against the Fcy-binding protein  of HSV-1. 
Data presented here also provide a detailed structural  basis 
for the idiotypic-anti-idiotypic reactivity of human KFs with 
the Fab fragment of mAb II-481. 
Additional support  for a structural  resemblance between 
some KFs  and  the HSV-Fcy-binding protein lies in  the 
striking similarities shown in their IgG binding specificities. 
Polyclonal KFs derived from patients  with R.A  generally 
possess a similar human IgG subclass specificity to that of 
HSV-1 Fcy-binding protein in that they preferentially bind 
to IgG-1, -2 and -4 but not or only weakly to IgG-3 (43, 
44). Like the HSV Fc3~-binding proteins,  most polyclonal 
RFs bind to the CH3 and CH2 interface region of IgG (43, 
45-47).  Studies using chemical modification of amino acids 
of IgG revealed that Tyr and His residues on IgG seemed 
to be critical for the binding with KFs (38, 40, 45, 48) and 
also for binding to the HSV Fc3,-binding protein (47). 
As an alternative to the idiotype-anti-idiotype model, it 
is conceivable that the viral herpes Fcy-binding protein gE 
may present the IgG molecule to the host (patients with RA) 
in such a way that the interface regions between the IgG CH2 
and CH3 domains become immunogenic (40). KF-positive 
patients  with RA have been demonstrated to show an as- 
sociation with the class II HLA antigen DR4 (49, 50). It 
is possible that HLA DK4 could somehow influence the im- 
mune response against Fc3,-binding proteins such as gE or 
to autologous anti-Fc3,-binding protein antibodies and that 
RFs in RA might in turn, therefore, be related somehow 
to immune responses of genetically predisposed individuals 
to herpesviruses or to other viral agents possessing IgG Fc'y- 
binding proteins. Presently, there is no evidence that HLA 
DR4 functions as a restriction element for HSV-1 immune 
responsiveness. 
Production of KF cannot be ascribed to idiotype-anti- 
1886  Monoclonal  Anti-Fc~"  Ab Contains CDR Regions Reacting with RFs idiotypic responses  alone since there is now a large body of 
experimental and clinical evidence which indicates that im- 
munization with globular proteins, certain carbohydrates,  or 
bacterial antigens may also result in KF induction. 
The information provided here concerning the reaction be- 
tween polyclonal or monoclonal IgM human P,  Fs and the 
Fv portions of mAb II-481 can be compared with the precise 
three-dimensional definition of an idiotope-anti-idiotope com- 
plex determined from the crystal structure of a complex be- 
tween the monoclonal antil~rsozyme Fab D1.3 and the anti- 
idiotopic Fab E225  at 2.5 A  resolution (51). In this latter 
instance,  the private idiotope consisted of 13  amino  acid 
residues mainly from the CDKs of D1.3.7 of the 13 residues 
made contacts with the original antigen which indicated a 
significant overlap between idiotype and antigen-combining 
site. In the case of mAb II-481  studied here, we do not yet 
have final definition of actual gE antigen binding residues 
within the mAb II-481 VH or VL CDKs. When this infor- 
mation becomes available with a crystal structure for the 
gE-mAb II-481 complex, a more selective or precise estimate 
of idiotope and antigen combining site may become available. 
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